A B S T R A C T
Proteinuria is a distinguishing feature in primary and secondary forms of chronic glomerulonephritis, which contribute to no more than the 20% of the end-stage kidney disease (ESKD) population. The contribution of non-proteinuric nephropathies to the global ESKD burden is still poorly focused and scarce research efforts are dedicated to the elucidation of risk factors and mechanistic pathways triggering ESKD in these diseases. We abstracted information on proteinuria in the main renal diseases other than glomerulonephritides that may evolve into ESKD. In type 2 diabetes, non-proteinuric diabetic kidney disease (DKD) is more frequent than proteinuric DKD, and risk factors for non-proteinuric forms of DKD now receive increasing attention. Similarly, proteinuria is most often inconspicuous or absent in the most frequent cause of ESKD, i.e. hypertensionrelated chronic kidney disease (CKD), as well as in progressive cystic diseases like autosomal dominant polycystic kidney disease and in pyelonephritis/tubulo-interstitial diseases. Maintaining a high degree of attention in the care of CKD patients with proteinuria is fundamental to effectively retard progression toward kidney failure. However, substantial research efforts are still needed to develop treatment strategies that may help the vast majority of CKD patients who eventually develop ESKD via mechanistic pathways other than proteinuria.
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I N T R O D U C T I O N
Biomarkers of renal damage are established major risk factors for cardiovascular (CV) and renal morbidity even in the absence of clearly impaired renal function, and albuminuria and proteinuria represent time-honored risk markers of high cardiorenal risk [1] . Chronic kidney disease (CKD) patients with proteinuria or albuminuria, like those with primary or secondary forms of glomerulonephritis, are notoriously at high risk for disease progression. Reabsorption of albumin escaped from the glomerular filter by the cubilin-megalin complex in renal tubular cells sets into motion a nephrotoxic pathway whereby the complex cubilin-megalin-albumin activates reactive oxygen species (ROS) synthesis, and enhances the synthesis of nuclear factor jB-controlled cytokines cascade and of endothelin-I and transforming growth factor (TGF)-b, ultimately leading to tubulo-interstitial atrophy and fibrosis, and renal function loss [2] (Figure 1, left panel) . While the pathogenic role of proteinuria in renal diseases is unquestionable, alternative, nonalbuminuric pathways conducive to renal function loss exist. Risk factors that might trigger a progressive decline of the glomerular filtration rate (GFR) in the absence of proteinuria/albuminuria ( Figure 1 , right panel) include hypertension, obesity, high serum triglycerides levels and glomerular hyperfiltration, an alteration that is not confined to diabetes, being commonly seen also in the early stages of hypertension [4] . These mechanisms are often at play in nephrosclerosis, a disease characterized by the absence of proteinuria and inconspicuous urine sediment, which is by far the most common form of progressive renal disease leading to end-stage kidney disease (ESKD).
Glomerulonephritides are most often proteinuric diseases. The incidence rate of ESKD due to glomerulonephritides plateaued in the 1990s and since then has declined steadily. Nowadays these diseases account for only 7.5 and 10% of incident dialysis patients in the USA and Europe, respectively [5, 6] . On the other hand, accumulating data suggest that the proportion of CKD patients without proteinuria is substantial. For example, in a survey made in the framework of the Third National Health and Nutrition Examination Survey (NHANES III) as
many as 37% of patients with a GFR <30 mL/min/1.73 m 2 had no albuminuria [7] . This is also true for a condition like type 2 diabetes, where proteinuria was seen as an obligatory step in the pathway conducive to kidney failure [8] . Indeed, among patients with type 2 diabetes with GFR <60 mL/min/1.73 m 2 included in NHANES III, 30% were normoalbuminuric [9] .
While proteinuria is an unquestionable, strong risk factor for CKD progression, non-proteinuric forms of CKD might be the most frequent cause of ESKD. The problem is similar to that of severe and moderate hypertension. Severe hypertension is a condition imposing an extremely high risk for CV death and non-fatal CV events, but being a relatively rare condition its global contribution to CV disease is by far inferior to that of mild to moderate hypertension, which are highly prevalent conditions that per se associate to a risk excess for CV events much lower than that of severe hypertension. This is precisely the reason why in the 1990s Geofrey Rose proposed that a small shift in the blood pressure distribution curve in the general population may have a greater beneficial effect in CV prevention than focusing only on treating high-risk patients [10] . Presently, the degree of attention driven within the nephrology community by proteinuric diseases far exceeds that of non-proteinuric ones. A simple PubMed search limited to the last 5 years made on 8 November 2016 with the term 'glomerulonephritis' returned 6767 original papers, reviews or editorials focusing on this condition, whereas the numbers of corresponding papers focusing on nephrosclerosis, the most common form of non-proteinuric renal disease, or with the term 'non-proteinuric' were just 219 and 298, respectively, notwithstanding obvious overlapping between the two searches. Since this issue is still poorly focused in the current literature and since proteinuric nephropathies are by far more frequently investigated than non-proteinuric ones, we felt it was important to overview the relative contribution of proteinuric and non-proteinuric nephropathies to the global burden of ESKD. We pragmatically approached this issue by reviewing the literature (Figure 2 ) on the epidemiology of proteinuria in chronic nephropathies that are responsible for ESKD in the two major renal registries, the US Renal Data System (USRDS) [5] and the European Renal Association-European Dialysis and Transplantation (ERA-EDTA) Registry [6] . These diseases include diabetes, hypertension, autosomal dominant polycystic kidney disease (ADPKD) and cystic diseases, and pyelonephritis/interstitial nephritis ( Table 1) . We deliberately did not review glomerulonephritis, a proteinuric condition contributing to the ESKD burden by about 20%.
D I A B E T E S
Diabetes is a pervasive cause of ESKD in western populations and a major contributor to the CKD epidemic worldwide [21] . Advanced renal disease attributable to diabetic disease accounts for 44 and 30% of new ESKD individuals needing to start chronic renal replacement therapy in the USA and Europe, respectively [5, 6] . As alluded to before, the paradigm that proteinuria is a necessary step in the course of CKD associated with type 2 diabetes, causing renal dysfunction and progression to ESKD, has been reframed. Epidemiological surveys unequivocally showed that a 
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AlteraƟons in adipokines and secondary pro-inflammatory changes FIGURE 1: Mechanisms whereby sustained proteinuria (left panel) and non-proteinuric pathways (right panel) may lead to chronic tubulointerstitial damage. Nephrotoxicity of proteinuria: albumin escaped from the glomerular filter is taken up by the cubilin-megalin complex in tubular cells. The complex cubilin-megalin-albumin triggers local production of ROS and activates regulated on activation, normal T cell expressed and secreted (RANTES), a fundamental chemotactic cytokine. Monochemotactic protein 1 (MCP-1), another chemo-attractant of inflammatory cells, is also activated and these factors trigger macrophage accumulation at the tubular level and in the interstitium. Nuclear factor jB (NF-jB) and the cytokine cascade recruited by this factor are also activated in parallel with TGF-b, a factor that stimulates the proliferation of fibrocytes and collagen accumulation. The cubilin-megalin-albumin complex also activates endothelin synthesis, which eventually results in vasoconstriction and parallel inflammatory changes in the vascular endothelium. Non-proteinuric pathways that may be conducive to kidney damage include hypertension, obesity/overweight, high serum triglycerides and hyperfiltration at the single nephron level. As for diabetes, these pathways are discussed in some detail in Porrini et al. [3] . E S K D i n n o n -p r o t e i n u r i c r e n a l d i s e a s e s ii195
reduced GFR is more common among diabetic patients than in non-diabetic subjects, but also revealed that a large number of such patients will never show levels of proteinuria above the traditional definition of overt diabetic nephropathy (>500 mg/g) during their life course [22] . The term 'diabetic kidney' has been proposed to encompass various lesions involving all kidney structures to characterize kidney disease in patients with diabetes [diabetic kidney disease (DKD)]. While the presence of glomerular damage underlies either the presence or the risk for proteinuria and dictates the linear progression that was classically described decades ago [8] , proteinuria cannot be considered as a marker of diabetic nephropathy 'tout court'. Rather, proteinuria in diabetes has to be seen as an indicator of glomerular lesions in diabetic patients with CKD. Historical trends showing improvements in glycaemic control over time in large databases and the widespread use of antagonists of the renin-angiotensin system may have contributed to a decrease in the prevalence of glomerular lesions and allowed the emergence of other types of renal lesions affecting the interstitium and the vasculature, i.e. lesions that may cause progressive renal damage without triggering proteinuria or producing just mild to moderate increases in the levels of this biomarker.
Parving et al. [11] , in a survey by the International Diabetes Federation and the International Society of Nephrology including about 30 000 type 2 diabetic patients from 33 countries, found that the overall prevalence of normo-, micro-and macroalbuminuria was 51, 39 and 10%, respectively, with wide racial differences. As expected, the prevalence of reduced GFR (<60 mL/min/1.73 m 2 ) increased stepwise from normo-(17.5%) to micro-(27.5%) and macroalbuminuria (30.7%), thus confirming the nephrotoxicity of proteinuria, but also highlighted that, in the absence of proteinuria, a reduced GFR is observed in about one diabetic patient out of five, a risk not dramatically different from that registered in patients with macroalbuminuria (one patient out of three). These findings, indicating that a substantial burden of non-proteinuric forms of renal damage in diabetes were largely confirmed in the analyses in the NHANES database, have been discussed previously [9] . In another epidemiologic study, comparing secular trends in the prevalence of DKD in the USA across three time windows (1988-94, 1999-2004 and 2005-08) [23] , the prevalence of DKD, defined as diabetes with albuminuria (albuminuria/creatininuria 30 mg/g), reduced GFR (<60 mL/min/1.73 m 2 ) or both, increased overtime from 2.2% (1988-94) to 2.8% (1999) (2000) (2001) (2002) (2003) (2004) , reaching 3.3% in 2005-08. Importantly, this concurred with the prevalence of diabetes in the same population, whereas the prevalence of DKD among diabetic patients did not change.
Overall 
H Y P E R T E N S I V E / R E N O V A S C U L A R D I S E A S E
Nearly 40% of adults in the USA have either known or undiagnosed hypertension [24] and >20% of patients with systemic hypertension have either a reduced GFR (<60 mL/min/1.73 m 2 ) or significant albuminuria/proteinuria [25] . Due to the high prevalence of this condition, notwithstanding that only a tiny minority of hypertensive individuals progress to ESKD, hypertensive nephropathy ranks as the second cause of ESKD requiring dialysis or renal transplantation worldwide [5, 6] . In the USA, hypertensive renal disease accounted for approximately 158 000 patients entering the USRDS during 2006-12 (28% of incident patients) [26] . In Europe, 21% of incident and 18% of prevalent dialysis patients have been attributed to hypertension [6] .
Renal changes in hypertension are often classified as benign or malignant nephrosclerosis. Benign nephrosclerosis is a slow process characterized by intimal fibrosis and medial thickening of medium size branches of the arterial tree in the kidney and hyaline arteriolosclerosis of small arterioles, which usually progress in the absence of proteinuria. Uncontrolled malignant nephrosclerosis-a rare condition characterized by severe thrombotic microangiopathy, segmental fibrinoid necrosis, occlusive endothelial swelling and capillary thrombi [27] -represents a strong risk factor for ESKD, and the severity of renal damage in this nephropathy is reflected by the almost obligatory presence, to various degrees, of proteinuria.
Several observational studies have reported higher urinary albumin excretion in individuals affected by essential hypertension as compared with healthy matched controls, but the overall prevalence of pathological microalbuminuria ranged from 9.2% to 40% [13-15, 17, 28-30] . Of note, in these studies, almost all subjects with essential hypertension had preserved renal function, even in the presence of increased albuminuria. Absolute urinary albumin values and the prevalence of microalbuminuria in these studies went along with hypertension severity [13] , an observation in line with an analysis in the time window 1999-2006 in the NHANES database in 16 567 subjects [16] . Therein the prevalence of microalbuminuria was dose-dependently associated with hypertension severity, being 4.5% in individuals with normal blood pressure, The prevalence of microalbuminuria increased with hypertension severity, being 4.5% for normal BP, 6.3% for pre-hypertension, 12.4% for stage 1 hypertension, 25.3% for stage 2 hypertension; the prevalence was 11.3% in subjects with controlled hypertension
Leoncini et al. [17] Cross-sectional 957 never previously treated, middle-aged patients with primary hypertension Albuminuria 9.2% (88 patients)
Mean creatinine clearance was 83 6
21.2 mL/min; prevalence of LVH and retinopathy was 13 and 49%
Cystic diseases: ADPKD Chapman et al. [18] Cross-sectional/ prospective 270 ADPKD patients Proteinuria 17.8% (48 patients) All proteinuric subjects were hypertensive and had larger renal volumes, lower creatinine clearances and the projection of a more aggressive course of renal disease; individuals with albuminuria had higher BP, larger renal volumes and increased filtration fraction Albuminuria 7% (19 patients)
Pyelonephritis
Arze et al. [19] Cross-sectional/ prospective 130 patients with primary chronic pyelonephritis diagnosed radiologically or by nephrectomy, of which 84 had unilateral and 46 had bilateral disease, followed for 6-240 months Proteinuria 21% (27 patients) A further 26 patients developed proteinuria during follow up; incident proteinuria was associated with hypertension and bilateral disease
Goodship et al. [20] Cross 6.3% in those with prehypertension, 12.4% and 25.3%, respectively, in those with stages 1 and 2 hypertension, but just 11.3% among those with treated, controlled hypertension. Although some hypertensive subjects may develop severe proteinuria during the course of the disease and even manifest nephrotic syndrome [17] , this evolution is definitely uncommon in the absence of other systemic or renal diseases [31, 32] .
C Y S T I C D I S E A S E S : A D P K D
ADPKD is the most common inherited kidney disease leading to ESKD. The incidence rate of ESKD attributable to ADPKD is about 12% in the USA [5] and 6% in Europe [6] . By 60 years of age, approximately 50% of patients with ADPKD have usually developed ESKD [33] . Unlike other renal diseases, in ADPKD the relationship between the presence and the magnitude of proteinuria/albuminuria and renal prognosis is debated. Only two studies specifically focused on proteinuria in ADPKD and only sparse evidence exists suggesting a negative effect of proteinuria on renal outcomes in ADPKD patients [34, 35] , and trials targeting proteinuria in ADPKD failed to provide clear benefits [36] . Prevalence of proteinuria ranged from 18% to 24% in the largest ADPKD trials testing the effects of various interventions on disease progression, such as the TEMPO [37] , the HALT-PKD [38] , the ALADIN [39] and the SIRENA [40] trials. However, these trials focused on specific ADPKD subpopulations and, given the restricted inclusion criteria of the same trials (e.g. early CKD stage, normal blood pressure or absence of other renal diseases), findings in these subpopulations may not reflect the ADPKD population at large.
Pathological albuminuria or proteinuria in ADPKD may represent in most cases a direct consequence of poorly controlled blood pressure, severe renovascular damage due to isolated high blood pressure peaks or, more rarely, superimposed glomerular diseases [41] . In ADPKD, besides the specific genetic alteration, the most relevant risk factor for adverse renal outcomes is blood pressure control [42] . Therefore, the presence of proteinuria in these patients may identify a group of patients with more severe or poorly controlled hypertension. In an cohort study of 270 ADPKD patients [18] , the mean 24-h urinary protein excretion was on average 259 6 22 mg/day, but only 48 (17.8%) of them had proteinuria >300 mg/day. Patients with clear-cut proteinuria had higher mean arterial pressure, larger renal volume and lower creatinine clearance. All proteinuric patients were hypertensive, whereas the corresponding figure in those without proteinuria was 67%. The prevalence of microalbuminuria in this cohort was 7%, and, along with findings in proteinuric patients, patients with microalbuminuria displayed higher mean arterial pressure and larger renal volumes, as well as increased filtration fraction.
P Y E L O N E P H R I T I S
Chronic pyelonephritis is usually the consequence of repeated episodes of vesicoureteric reflux and urinary infection, which may start in early childhood. This condition accounts for about 4-6% of prevalent and incident dialysis patients worldwide [5, 6] .
Pathological proteinuria in 'pure' pyelonephritis is an uncommon finding and rarely exceeds 1 g/24 h [43] [44] [45] ; higher values may reflect the concomitant presence of vesicoureteric reflux, particularly if bilateral, due to transudation of tissue fluid out of an infected kidney [46] . Conversely, nephrotic-range proteinuria in pyelonephritis is usually a hallmark of superimposed focal segmental glomerular sclerosis or diabetic nephropathy, or hypertension [47] .
In a series published in the 1980s, 130 patients with primary chronic pyelonephritis diagnosed radiologically or by nephrectomy, of which 84 had unilateral and 46 had bilateral disease, were followed for 6-240 months [19] . At presentation, only 27 patients (21%) had proteinuria, whereas a further 26 patients developed this complication during follow-up. Incident proteinuria was associated with hypertension and bilateral disease. The natural history of chronic pyelonephritis was also investigated in 255 patients from the Newcastle chronic pyelonephritis database. Overall, the prevalence of proteinuria was approximately 37%. Of note, proteinuria was more frequent in individuals with high serum creatinine (>90 mmoL/L) and was associated with the presence of hypertension [20] .
C O N C L U S I O N S
Apart from renal diseases where proteinuria is a distinguishing feature, like primary and secondary forms of chronic glomerulonephritis, which contribute to no more than 20% of the ESKD population, the presence of relevant proteinuria is infrequent in the remaining diseases that underlie the ESKD burden in the US and European registries. In type 2 diabetes, nonproteinuric DKD prevails on the proteinuric form of the same disease and risk factors for non-proteinuric DKD are being increasingly focused on, e.g. in Porrini et al. [3] . A relevant degree of proteinuria is even less frequent in hypertension-related CKD as well as in progressive cystic diseases like ADPKD and pyelonephritis/tubulo-interstitial diseases. Even though therapeutic targeting of proteinuria remains a centrepiece in the fight against progressive renal diseases [48] , substantial research efforts are needed to develop treatment strategies that may help the vast majority of CKD patients who eventually develop ESKD via mechanistic pathways other than proteinuria.
